NQO1 and cancer: Synthetic analogues of seriniquinone are required due to its poor water solubility, with 10a and 10b showing strong PCCs of 0.75 and 0.72 to DPIQ anti-cancer activity, respectively, but weak to moderate PCCs of 0.47 and 0.48 to NQO1 expression, respectively (Figure 4).